Tags

Type your tag names separated by a space and hit enter

Response to HAART and GB virus type C coinfection in a cohort of antiretroviral-naive HIV-infected individuals.
Antivir Ther. 2005; 10(1):109-17.AT

Abstract

The prognostic role of GB virus type C (GBV-C) viraemia in HIV-infected subjects treated with highly active antiretroviral therapy (HAART) is still undefined. The aim of this analysis is to assess the relationship between GBV-C infection and response to antiretroviral therapy among HIV-infected subjects initiating HAART when antiretroviral-naive. A prospective, observational study of 400 HIV-infected patients with measurements of GBV-C RNA, hepatitis C virus (HCV) antibodies and HCV RNA determined from plasma stored prior to HAART initiation. Time to virological (achieving HIV RNA < or =500 copies/ml) and immunological success (a CD4+ count increase of > or =200 cells/microl), and the time to virological relapse (confirmed HIV RNA >500 copies/ml) were assessed by Kaplan-Meier methods and Cox proportional hazard regression model. Of the subjects, 117 (29.3%) were GBV-C positive and, overall, 351 (87.8%) patients achieved virological success. After controlling for a number of confounders including HCV RNA, GBV-C viraemic patients experienced a significantly lower risk of HIV rebound than those who were GBV-C negative [relative hazard (RH)=0.56, 95% CI: 0.34-0.93, P=0.03]. Conversely, the probability of achieving initial virological success or CD4+ count response after HAART did not differ between GBV-C-negative and -positive subjects. These results suggest that GBV-C coinfection may play a role in determining the rate of HIV rebound possibly by competing with HIV replication after HIV load has been successfully suppressed by HAART.

Authors+Show Affiliations

National Institute of Infectious Diseases, L Spallanzani, Roma, Italy. antonucci@inmi.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15751768

Citation

Antonucci, Giorgio, et al. "Response to HAART and GB Virus Type C Coinfection in a Cohort of Antiretroviral-naive HIV-infected Individuals." Antiviral Therapy, vol. 10, no. 1, 2005, pp. 109-17.
Antonucci G, Girardi E, Cozzi-Lepri A, et al. Response to HAART and GB virus type C coinfection in a cohort of antiretroviral-naive HIV-infected individuals. Antivir Ther. 2005;10(1):109-17.
Antonucci, G., Girardi, E., Cozzi-Lepri, A., Capobianchi, M. R., Morsica, G., Pizzaferri, P., Ladisa, N., Sighinolfi, L., Chiodera, A., Solmone, M., Lalle, E., Ippolito, G., & Monforte, A. d. (2005). Response to HAART and GB virus type C coinfection in a cohort of antiretroviral-naive HIV-infected individuals. Antiviral Therapy, 10(1), 109-17.
Antonucci G, et al. Response to HAART and GB Virus Type C Coinfection in a Cohort of Antiretroviral-naive HIV-infected Individuals. Antivir Ther. 2005;10(1):109-17. PubMed PMID: 15751768.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Response to HAART and GB virus type C coinfection in a cohort of antiretroviral-naive HIV-infected individuals. AU - Antonucci,Giorgio, AU - Girardi,Enrico, AU - Cozzi-Lepri,Alessandro, AU - Capobianchi,Maria Rosaria, AU - Morsica,Giulia, AU - Pizzaferri,Paolo, AU - Ladisa,Nicoletta, AU - Sighinolfi,Laura, AU - Chiodera,Alessandro, AU - Solmone,Mariacarmela, AU - Lalle,Eleonora, AU - Ippolito,Giuseppe, AU - Monforte,Antonella d'Arminio, AU - ,, AU - ,, PY - 2005/3/9/pubmed PY - 2005/5/19/medline PY - 2005/3/9/entrez SP - 109 EP - 17 JF - Antiviral therapy JO - Antivir Ther VL - 10 IS - 1 N2 - The prognostic role of GB virus type C (GBV-C) viraemia in HIV-infected subjects treated with highly active antiretroviral therapy (HAART) is still undefined. The aim of this analysis is to assess the relationship between GBV-C infection and response to antiretroviral therapy among HIV-infected subjects initiating HAART when antiretroviral-naive. A prospective, observational study of 400 HIV-infected patients with measurements of GBV-C RNA, hepatitis C virus (HCV) antibodies and HCV RNA determined from plasma stored prior to HAART initiation. Time to virological (achieving HIV RNA < or =500 copies/ml) and immunological success (a CD4+ count increase of > or =200 cells/microl), and the time to virological relapse (confirmed HIV RNA >500 copies/ml) were assessed by Kaplan-Meier methods and Cox proportional hazard regression model. Of the subjects, 117 (29.3%) were GBV-C positive and, overall, 351 (87.8%) patients achieved virological success. After controlling for a number of confounders including HCV RNA, GBV-C viraemic patients experienced a significantly lower risk of HIV rebound than those who were GBV-C negative [relative hazard (RH)=0.56, 95% CI: 0.34-0.93, P=0.03]. Conversely, the probability of achieving initial virological success or CD4+ count response after HAART did not differ between GBV-C-negative and -positive subjects. These results suggest that GBV-C coinfection may play a role in determining the rate of HIV rebound possibly by competing with HIV replication after HIV load has been successfully suppressed by HAART. SN - 1359-6535 UR - https://www.unboundmedicine.com/medline/citation/15751768/Response_to_HAART_and_GB_virus_type_C_coinfection_in_a_cohort_of_antiretroviral_naive_HIV_infected_individuals_ L2 - http://www.diseaseinfosearch.org/result/9735 DB - PRIME DP - Unbound Medicine ER -